Literature DB >> 22105577

Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Paul L Crispen1, Michael L Blute.   

Abstract

With the advent of targeted therapy for the treatment of metastatic renal cancer, the routine use of cytoreductive nephrectomy has been questioned. However, available data suggest that cytoreductive nephrectomy remains an integral part of treatment in properly selected patients. This review details the rationale for the continued use of cytoreductive nephrectomy in acceptable surgical candidates in the era of targeted therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22105577     DOI： 10.1007/s11934-011-0225-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  43 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

Review 3.  The role of cytoreductive nephrectomy in the era of molecular targeted therapy.

Authors:  Anthony J Polcari; Alex Gorbonos; John E Milner; Robert C Flanigan
Journal:  Int J Urol       Date:  2009-02-04       Impact factor: 3.369

4.  Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.

Authors:  Christopher G Wood; Vitaly Margulis
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

5.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 6.  The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.

Authors:  Jose A Karam; Christopher G Wood
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

Review 7.  Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.

Authors:  Maxine Sun; Shahrokh F Shariat; Christopher Cheng; Vincenzo Ficarra; Masaru Murai; Stéphane Oudard; Allan J Pantuck; Richard Zigeuner; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2011-06-30       Impact factor: 20.096

8.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Authors:  Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

9.  Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

Authors:  Anil A Thomas; Brian I Rini; Brian R Lane; Jorge Garcia; Robert Dreicer; Eric A Klein; Andrew C Novick; Steven C Campbell
Journal:  J Urol       Date:  2008-12-18       Impact factor: 7.450

10.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544
View more
  10 in total

1.  Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer.

Authors:  Toshihiro Kanda; Syohei Fukuda; Naotaka Fukui; Yu Ohkubo; Tomoko Kazumoto; Yoshihiro Saito; Ayataka Ishikawa; Masafumi Kurosumi; Yukio Kageyama; Yasuhisa Fujii; Kazunori Kihara
Journal:  Int J Clin Oncol       Date:  2016-01-11       Impact factor: 3.402

Review 2.  New challenges in kidney cancer management: integration of surgery and novel therapies.

Authors:  Javier Puente Vázquez; T Alonso Gordoa; J Moreno; L Poma; E Diaz Rubio; A Gomez; J Blazquez; J L Gonzalez Larriba
Journal:  Curr Treat Options Oncol       Date:  2015-03

3.  Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Vitaly Margulis; Shahrokh F Shariat; Yury Rapoport; Michael Rink; Daniel D Sjoberg; Nizar M Tannir; E Jason Abel; Stephen H Culp; Pheroze Tamboli; Christopher G Wood
Journal:  Eur Urol       Date:  2012-11-23       Impact factor: 20.096

4.  Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status.

Authors:  Yoshio Ohno; Jun Nakashima; Makoto Ohori; Ayako Tanaka; Takeshi Hashimoto; Tatsuo Gondo; Tadashi Hatano; Masaaki Tachibana
Journal:  Int J Clin Oncol       Date:  2013-01-09       Impact factor: 3.402

Review 5.  Role of radical prostatectomy in clinically non-organ-confined prostate cancer.

Authors:  Christian Gratzke; Jutta Engel; Christian G Stief
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

6.  Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy.

Authors:  Iori Sakai; Hideaki Miyake; Nobuyuki Hinata; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2013-08-30       Impact factor: 3.402

Review 7.  Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities.

Authors:  Angela Graves; Hannah Hessamodini; Germaine Wong; Wai H Lim
Journal:  Immunotargets Ther       Date:  2013-07-22

8.  Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.

Authors:  Wen-Jun Xiao; Yao Zhu; Bo Dai; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Int Braz J Urol       Date:  2015 Mar-Apr       Impact factor: 1.541

9.  Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy.

Authors:  Jun Teishima; Kohei Kobatake; Tetsutaro Hayashi; Yasuyuki Seno; Kenichiro Ikeda; Hirotaka Nagamatsu; Keisuke Hieda; Koichi Shoji; Katsutoshi Miyamoto; Shogo Inoue; Kanao Kobayashi; Shinya Ohara; Mitsuru Kajiwara; Akio Matsubara
Journal:  Oncol Lett       Date:  2014-06-02       Impact factor: 2.967

Review 10.  Cytoreductive surgery in the era of targeted molecular therapy.

Authors:  Arun Z Thomas; Mehrad Adibi; Leonardo D Borregales; Jose A Karam; Christopher G Wood
Journal:  Transl Androl Urol       Date:  2015-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.